Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Bipolar psychopharmacotherapy [[electronic resource] ] : caring for the patient / / edited by Hagop Akiskal and Mauricio Tohen
| Bipolar psychopharmacotherapy [[electronic resource] ] : caring for the patient / / edited by Hagop Akiskal and Mauricio Tohen |
| Edizione | [2nd ed.] |
| Pubbl/distr/stampa | Chichester, West Sussex, : John Wiley & Sons, c2011 |
| Descrizione fisica | 1 online resource (546 p.) |
| Disciplina | 616.895 |
| Altri autori (Persone) |
AkiskalHagop S
TohenMauricio |
| Soggetto topico |
Bipolar disorder - Chemotherapy
Lithium - Therapeutic use Antipsychotic drugs Psychopharmacology |
| ISBN |
0-470-97698-5
1-119-95664-1 1-283-37293-2 9786613372932 0-470-97510-5 0-470-97511-3 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Bipolar Psychopharmacotherapy; Contents; List of Contributors; Preface to the Second Edition; Chapter 1 The scope of bipolar disorders; 1.1 Diagnostic and public health aspects; 1.2 Psychological and social aspects; Appendix 1.A: Laboratory considerations in the clinical use of lithium; References; Chapter 2 Lithium treatment: Focus on long-term prophylaxis; 2.1 Introduction; 2.2 Cade's pioneering study; 2.3 Discovery of the prophylactic action of lithium; 2.4 Practical issues; 2.5 Are new and better prophylactic agents about to oust lithium?; 2.6 Combination treatment
2.7 Prophylaxis in recurrent depressive disorder 2.8 The effect of lithium on the patients' suicidal behavior; 2.9 Benefits of prophylactic lithium treatment; 2.10 Conclusion; References; Chapter 3 Valproate: Clinical pharmacological profile; 3.1 Historical background; 3.2 Structure-activity relationships; 3.3 Pharmacodynamic properties; 3.4 Pharmacokinetics and metabolic clearance; 3.5 Serum concentration and efficacy; 3.6 Efficacy and indications; 3.7 Efficacy in bipolar disorder; 3.8 Combination strategy in acute mania; 3.9 Prophylaxis in bipolar disorder 3.10 Treatment of bipolar depression 3.11 Valproate in treatment of bipolar disorder in children and adolescents; 3.12 Use in bipolar illness comorbid with alcoholism; 3.13 Bipolar disorder comorbid with ADHD; 3.14 Bipolar disorder comorbid with borderline personality disorder; 3.15 Adverse effects; 3.16 Comparative adverse effects; 3.17 Adverse effects in combination therapy, compared with monotherapy; 3.18 Adverse effects by bodily system; 3.19 Summary; References; Chapter 4 Pharmacological profile and clinical utility of lamotrigine in mood disorders; 4.1 Introduction 4.2 Clinical pharmacology of lamotrigine 4.3 Lamotrigine and mood disorders; 4.4 Safety; 4.5 Clinical applications for lamotrigine in mood disorders; 4.6 Summary; References; Chapter 5 Carbamazepine and other anticonvulsants; 5.1 Introduction; 5.2 Conclusions; References; Chapter 6 Olanzapine in treatment for bipolar disorder; 6.1 Introduction; 6.2 Rationale in the clinical trial development of olanzapine; 6.3 Efficacy in the treatment of acute mania; 6.4 Efficacy in the treatment of bipolar depression; 6.5 Efficacy in bipolar maintenance/relapse prevention; 6.6 Safety and tolerability 6.7 Summary References; Chapter 7 Haloperidol and other first generation antipsychotics in mania; 7.1 Introduction; 7.2 Acute tranquillization in mania; 7.3 Sedation is not required for antipsychotics to improve mania; 7.4 Chlorpromazine in mania; 7.5 Haloperidol in mania; 7.6 Hormone changes and mechanisms of antimanic effects of antipsychotics; 7.7 Antipsychotics as mood stabilizers; 7.8 Placebo-controlled studies in mania; 7.9 Recent comparative trials without placebo; 7.10 Pharmacoeconomics; 7.11 Conclusions; Declaration of interest; References Chapter 8 Clinical utility of clozapine in bipolar disorder |
| Record Nr. | UNINA-9910131046403321 |
| Chichester, West Sussex, : John Wiley & Sons, c2011 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Bipolar psychopharmacotherapy : caring for the patient / / edited by Hagop Akiskal and Mauricio Tohen
| Bipolar psychopharmacotherapy : caring for the patient / / edited by Hagop Akiskal and Mauricio Tohen |
| Edizione | [2nd ed.] |
| Pubbl/distr/stampa | Chichester, West Sussex, : John Wiley & Sons, c2011 |
| Descrizione fisica | 1 online resource (546 p.) |
| Disciplina | 616.895 |
| Altri autori (Persone) |
AkiskalHagop S
TohenMauricio |
| Soggetto topico |
Bipolar disorder - Chemotherapy
Lithium - Therapeutic use Antipsychotic drugs Psychopharmacology |
| ISBN |
0-470-97698-5
1-119-95664-1 1-283-37293-2 9786613372932 0-470-97510-5 0-470-97511-3 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Bipolar Psychopharmacotherapy; Contents; List of Contributors; Preface to the Second Edition; Chapter 1 The scope of bipolar disorders; 1.1 Diagnostic and public health aspects; 1.2 Psychological and social aspects; Appendix 1.A: Laboratory considerations in the clinical use of lithium; References; Chapter 2 Lithium treatment: Focus on long-term prophylaxis; 2.1 Introduction; 2.2 Cade's pioneering study; 2.3 Discovery of the prophylactic action of lithium; 2.4 Practical issues; 2.5 Are new and better prophylactic agents about to oust lithium?; 2.6 Combination treatment
2.7 Prophylaxis in recurrent depressive disorder 2.8 The effect of lithium on the patients' suicidal behavior; 2.9 Benefits of prophylactic lithium treatment; 2.10 Conclusion; References; Chapter 3 Valproate: Clinical pharmacological profile; 3.1 Historical background; 3.2 Structure-activity relationships; 3.3 Pharmacodynamic properties; 3.4 Pharmacokinetics and metabolic clearance; 3.5 Serum concentration and efficacy; 3.6 Efficacy and indications; 3.7 Efficacy in bipolar disorder; 3.8 Combination strategy in acute mania; 3.9 Prophylaxis in bipolar disorder 3.10 Treatment of bipolar depression 3.11 Valproate in treatment of bipolar disorder in children and adolescents; 3.12 Use in bipolar illness comorbid with alcoholism; 3.13 Bipolar disorder comorbid with ADHD; 3.14 Bipolar disorder comorbid with borderline personality disorder; 3.15 Adverse effects; 3.16 Comparative adverse effects; 3.17 Adverse effects in combination therapy, compared with monotherapy; 3.18 Adverse effects by bodily system; 3.19 Summary; References; Chapter 4 Pharmacological profile and clinical utility of lamotrigine in mood disorders; 4.1 Introduction 4.2 Clinical pharmacology of lamotrigine 4.3 Lamotrigine and mood disorders; 4.4 Safety; 4.5 Clinical applications for lamotrigine in mood disorders; 4.6 Summary; References; Chapter 5 Carbamazepine and other anticonvulsants; 5.1 Introduction; 5.2 Conclusions; References; Chapter 6 Olanzapine in treatment for bipolar disorder; 6.1 Introduction; 6.2 Rationale in the clinical trial development of olanzapine; 6.3 Efficacy in the treatment of acute mania; 6.4 Efficacy in the treatment of bipolar depression; 6.5 Efficacy in bipolar maintenance/relapse prevention; 6.6 Safety and tolerability 6.7 Summary References; Chapter 7 Haloperidol and other first generation antipsychotics in mania; 7.1 Introduction; 7.2 Acute tranquillization in mania; 7.3 Sedation is not required for antipsychotics to improve mania; 7.4 Chlorpromazine in mania; 7.5 Haloperidol in mania; 7.6 Hormone changes and mechanisms of antimanic effects of antipsychotics; 7.7 Antipsychotics as mood stabilizers; 7.8 Placebo-controlled studies in mania; 7.9 Recent comparative trials without placebo; 7.10 Pharmacoeconomics; 7.11 Conclusions; Declaration of interest; References Chapter 8 Clinical utility of clozapine in bipolar disorder |
| Record Nr. | UNINA-9910813763403321 |
| Chichester, West Sussex, : John Wiley & Sons, c2011 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
The Maudsley guidelines on advanced prescribing in psychosis / / Paul Morrison, David M. Taylor, Philip McGuire
| The Maudsley guidelines on advanced prescribing in psychosis / / Paul Morrison, David M. Taylor, Philip McGuire |
| Autore | Morrison Paul <1956-> |
| Pubbl/distr/stampa | Hoboken, NJ : , : Wiley Blackwell, , 2020 |
| Descrizione fisica | 1 online resource (114 pages) |
| Disciplina | 616.89 |
| Soggetto topico |
Psychoses - Treatment
Antipsychotic drugs Physician and patient |
| ISBN |
1-119-57843-4
1-119-57852-3 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Psychosis -- Towards evidence based treatments for psychosis -- The antipsychotics -- Bipolar disorder -- The role of talking therapies in the treatment of psychosis -- Side effects of antipsychotic treatment -- Services : pathway specific care -- Measuring outcomes. |
| Record Nr. | UNINA-9910793826703321 |
Morrison Paul <1956->
|
||
| Hoboken, NJ : , : Wiley Blackwell, , 2020 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
The Maudsley guidelines on advanced prescribing in psychosis / / Paul Morrison, David M. Taylor, Philip McGuire
| The Maudsley guidelines on advanced prescribing in psychosis / / Paul Morrison, David M. Taylor, Philip McGuire |
| Autore | Morrison Paul <1956-> |
| Pubbl/distr/stampa | Hoboken, NJ : , : Wiley Blackwell, , 2020 |
| Descrizione fisica | 1 online resource (114 pages) |
| Disciplina | 616.89 |
| Soggetto topico |
Psychoses - Treatment
Antipsychotic drugs Physician and patient |
| ISBN |
1-119-57843-4
1-119-57852-3 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Psychosis -- Towards evidence based treatments for psychosis -- The antipsychotics -- Bipolar disorder -- The role of talking therapies in the treatment of psychosis -- Side effects of antipsychotic treatment -- Services : pathway specific care -- Measuring outcomes. |
| Record Nr. | UNINA-9910820337603321 |
|
Morrison Paul <1956->
|
||
| Hoboken, NJ : , : Wiley Blackwell, , 2020 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Nursing facility assessments and care plans for residents receiving atypical antipsychotic drugs
| Nursing facility assessments and care plans for residents receiving atypical antipsychotic drugs |
| Pubbl/distr/stampa | [Washington, D.C.] : , : Department of Health and Human Services, Office of Inspector General, , 2012 |
| Descrizione fisica | 1 online resource (31 pages) : illustrations |
| Soggetto topico |
Antipsychotic drugs
Nursing home residents - Abuse of - United States - Prevention Nursing homes - Pharmaceutical services - United States - Auditing Long-term care facilities - Pharmaceutical services - United States - Auditing Drugs - Prescribing - United States |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Altri titoli varianti | Nursing facility assessments and care plans for residents receiving atypical antipsychotic drugs |
| Record Nr. | UNINA-9910707411003321 |
| [Washington, D.C.] : , : Department of Health and Human Services, Office of Inspector General, , 2012 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Pharmacotherapy of child and adolescent psychiatric disorders / / [edited by] David Rosenberg and Samuel Gershon
| Pharmacotherapy of child and adolescent psychiatric disorders / / [edited by] David Rosenberg and Samuel Gershon |
| Edizione | [3rd ed.] |
| Pubbl/distr/stampa | Chichester, West Sussex, : John Wiley & Sons, Inc., 2012 |
| Descrizione fisica | 1 online resource (475 p.) |
| Disciplina |
618.92/8918
618.928918 |
| Altri autori (Persone) |
RosenbergDavid R
GershonSamuel |
| Soggetto topico |
Pediatric psychopharmacology
Antipsychotic drugs |
| ISBN |
1-119-96100-9
1-280-67720-1 9786613654137 1-119-95833-4 1-119-95832-6 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Pharmacotherapy of Child and Adolescent Psychiatric Disorders; List of Contributors; Foreword; Chapter 1 Historical Perspectives on Child and Adolescent Psychopharmacology; References; Chapter 2 Pharmacoepidemiology of Psychotropic Medications in Youth; Introduction; Prevalence and trends for medications prescribed for ADHD; Nonstimulant medications for ADHD; Antidepressant medication; Antipsychotic medication; Alpha-agonists; Anticonvulsant "mood stabilizers"; Concomitant psychotropic medication; Preschool psychotropic medication use
International patterns of psychotropic medication for youthConclusion; References; Chapter 3 Off-Label Prescribing of Drugs in Child and Adolescent Psychiatry; Introduction; Extent of off-label prescribing; Need for psychoactive drug treatments for children and adolescents; Legislation supporting pediatric drug development; Recommendations to follow when considering off-label prescribing; References; Chapter 4 The Use of Generic Drugs in Pediatric Psychopharmacology; What is a generic drug?; Why are we discussing generic drugs?; Basic requirements for generic drugs The status of regulations regarding generic drugs and childrenAbbreviated new drug application (ANDA) requirements; Pediatric assessments of adult drugs (history up to current status); Best Pharmaceuticals for Children Act; Pediatric Research Equity Act; Intersection of requirements for generics and pediatric assessment; Future directions; Concluding thoughts; References; Chapter 5 Psychoactive Drug Use in Children: Basic Concepts in Clinical Pharmacology; Introduction; Basic concepts in pharmacokinetics; Dosing considerations for psychoactive drugs in children; Summary; References Chapter 6 PsychostimulantsIntroduction; Epidemiology of stimulant use; Structure and biochemical mechanism of action; Neuroimaging studies of stimulant effects; Studies of short-term efficacy; Studies of long-term efficacy; Clinical use; Common side-effects; Cardiovascular safety issues; Growth suppression; Substance use and diversion; Comparison with nonstimulant treatment; Treatment of comorbidity; Pharmacogenetics; Conclusions; References; Chapter 7 Tricyclic Antidepressants and Monoamine Oxidase Inhibitors for the Treatment of Child and Adolescent Psychiatric Disorders Tricyclic antidepressants (TCAs)Drug interactions, contraindications; Monoamine oxidase inhibitors (MAOIs); General summary; References; Chapter 8 Selective Serotonin Reuptake Inhibitors (SSRIs); Pharmacokinetics; Initiation and titration; Indications and efficacy; Adverse effects; Withdrawal; References; Chapter 9 Novel (Atypical) Antidepressants; Novel (atypical) antidepressants; General overview; Bupropion; Duloxetine; Mirtazapine; Trazodone; Venlafaxine; Desvenlafaxine; Alternative treatments; Summary; References; Chapter 10 Antipsychotic Agents; Introduction; Chemical properties Typical antipsychotics |
| Record Nr. | UNINA-9910141315803321 |
| Chichester, West Sussex, : John Wiley & Sons, Inc., 2012 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Psicofarmacología, terapias psicológicas y tratamientos combinados (II) : eficacia comparada en los trastornos mentales / / Alberto Fernandez Teruel
| Psicofarmacología, terapias psicológicas y tratamientos combinados (II) : eficacia comparada en los trastornos mentales / / Alberto Fernandez Teruel |
| Autore | Fernández Teruel Alberto |
| Edizione | [First edition.] |
| Pubbl/distr/stampa | Barcelona : , : Editorial UOC, , [2010] |
| Descrizione fisica | 1 online resource (83 p.) |
| Disciplina | 615.7882 |
| Collana | Manuales (Editorial UOC) |
| Soggetto topico | Antipsychotic drugs |
| ISBN | 84-9029-103-9 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | spa |
| Record Nr. | UNINA-9910785633803321 |
|
Fernández Teruel Alberto
|
||
| Barcelona : , : Editorial UOC, , [2010] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Psicofarmacología, terapias psicológicas y tratamientos combinados (II) : eficacia comparada en los trastornos mentales / / Alberto Fernandez Teruel
| Psicofarmacología, terapias psicológicas y tratamientos combinados (II) : eficacia comparada en los trastornos mentales / / Alberto Fernandez Teruel |
| Autore | Fernández Teruel Alberto |
| Edizione | [First edition.] |
| Pubbl/distr/stampa | Barcelona : , : Editorial UOC, , [2010] |
| Descrizione fisica | 1 online resource (83 p.) |
| Disciplina | 615.7882 |
| Collana | Manuales (Editorial UOC) |
| Soggetto topico | Antipsychotic drugs |
| ISBN | 84-9029-103-9 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | spa |
| Record Nr. | UNINA-9910824657903321 |
|
Fernández Teruel Alberto
|
||
| Barcelona : , : Editorial UOC, , [2010] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
The science and ethics of antipsychotic use in children / / edited by Nina Di Pietro and Judy Illes ; contributors, Mai Berger [and twenty others]
| The science and ethics of antipsychotic use in children / / edited by Nina Di Pietro and Judy Illes ; contributors, Mai Berger [and twenty others] |
| Pubbl/distr/stampa | Amsterdam, [Netherlands] : , : Academic Press, , 2015 |
| Descrizione fisica | 1 online resource (228 p.) |
| Disciplina | 615.7882 |
| Soggetto topico |
Antipsychotic drugs
Children - Drug use |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Front Cover; The Science and Ethics of Antipsychotic Use in Children; Copyright; Contents; Contributors; Foreword; Acknowledgments; Introduction: A Call for Partnership; References; Chapter 1: A Brief History of the Science and Ethics of Antipsychotics and Off-Label Prescribing; A New Era in Psychopharmacology Research Begins; A Second Generation Emerges; The Expansion of Antipsychotics: Off-Label Use in Children; Benefits in the Face of Risks; A Call for Partnership; References; Chapter 2: Pharmacoepidemiology of Antipsychotic Use in Canadian Children and Adolescents; Introduction
Differences in SGA Regulation Between Canada and Other CountriesCanadian Second-Generation Antipsychotic Medications Prescription Trends for Children and Adolescents; National Prescribing Trends; Provincial Prescribing Trends; Manitoba; Nova Scotia; British Columbia; Comparing Canadian SGA Prescription Trends to those in Other Countries; Conclusions; References; Chapter 3: Do We Know If They Work and If They Are Safe: Second-Generation Antipsychotics for Treatment of Autism Spectrum ...; Introduction; Methods; Efficacy of SGAs for Children and Adolescents With ASDs Efficacy of SGAs for Children and Adolescents With DBDsSummary of Adverse Effects and Safety Data from ASD and DBD Trials Combined; Discussion; SGAs Included in RCTs; Efficacy in ASD Trials; Efficacy in DBD trials; Critique and Ethical Considerations; Conclusion; References; ASD Studies: Aripiprazole; ASD Studies: Olanzapine; ASD Studies: Risperidone; DBD Studies: Aripiprazole; DBD Studies: Quetiapine; DBD Studies: Risperidone; Chapter 4: Ensuring the Safety of Children Treated with Second-Generation Antipsychotics; Introduction; Side Effects associated with SGA use in Children and Youth Monitoring the Health of Children and Youth on SGAsGuidelines for Metabolic Monitoring; Recommendations for Monitoring Metabolic Changes; Height; Weight; Body Mass Index; Waist Circumference; Blood Pressure; Management of Metabolic Complications; Why Standardized Metabolic Monitoring Matters; Improving Patient Care; Educating Families; Overcoming Barriers to Completion of Monitoring; Conclusion; References; Chapter 5: Pediatric Clinical Trial Activity for Antipsychotics and the Sharing of Results: A Complex Ethical Landscape; Introduction; Patient Safety, Ethics, and Clinical Trial Regulation The Push for Pediatric Clinical TrialsThe Push for Clinical Trial Registration; Reporting of Results; Mapping the Landscape: Clinical Trials for Antipsychotics in Children and Youth; Methods; Results; Reflections On The Current State Of Pediatric Clinical Trials For Antipsychotics; The Landscape of Clinical Trial Activity; Developmental Gaps; The Strength of Evidence; Uniformity in Outcome Measures; Gaps in Results Reporting; Recruitment and Willingness to Participate in Research; Informed Consent; Limitations; Recommendations; References Chapter 6: Pathways to Overmedication and Polypharmacy: Case Examples from Adolescents with Fetal Alcohol Spectrum Disorders |
| Record Nr. | UNINA-9910788115303321 |
| Amsterdam, [Netherlands] : , : Academic Press, , 2015 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
The science and ethics of antipsychotic use in children / / edited by Nina Di Pietro and Judy Illes ; contributors, Mai Berger [and twenty others]
| The science and ethics of antipsychotic use in children / / edited by Nina Di Pietro and Judy Illes ; contributors, Mai Berger [and twenty others] |
| Pubbl/distr/stampa | Amsterdam, [Netherlands] : , : Academic Press, , 2015 |
| Descrizione fisica | 1 online resource (228 p.) |
| Disciplina | 615.7882 |
| Soggetto topico |
Antipsychotic drugs
Children - Drug use |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Front Cover; The Science and Ethics of Antipsychotic Use in Children; Copyright; Contents; Contributors; Foreword; Acknowledgments; Introduction: A Call for Partnership; References; Chapter 1: A Brief History of the Science and Ethics of Antipsychotics and Off-Label Prescribing; A New Era in Psychopharmacology Research Begins; A Second Generation Emerges; The Expansion of Antipsychotics: Off-Label Use in Children; Benefits in the Face of Risks; A Call for Partnership; References; Chapter 2: Pharmacoepidemiology of Antipsychotic Use in Canadian Children and Adolescents; Introduction
Differences in SGA Regulation Between Canada and Other CountriesCanadian Second-Generation Antipsychotic Medications Prescription Trends for Children and Adolescents; National Prescribing Trends; Provincial Prescribing Trends; Manitoba; Nova Scotia; British Columbia; Comparing Canadian SGA Prescription Trends to those in Other Countries; Conclusions; References; Chapter 3: Do We Know If They Work and If They Are Safe: Second-Generation Antipsychotics for Treatment of Autism Spectrum ...; Introduction; Methods; Efficacy of SGAs for Children and Adolescents With ASDs Efficacy of SGAs for Children and Adolescents With DBDsSummary of Adverse Effects and Safety Data from ASD and DBD Trials Combined; Discussion; SGAs Included in RCTs; Efficacy in ASD Trials; Efficacy in DBD trials; Critique and Ethical Considerations; Conclusion; References; ASD Studies: Aripiprazole; ASD Studies: Olanzapine; ASD Studies: Risperidone; DBD Studies: Aripiprazole; DBD Studies: Quetiapine; DBD Studies: Risperidone; Chapter 4: Ensuring the Safety of Children Treated with Second-Generation Antipsychotics; Introduction; Side Effects associated with SGA use in Children and Youth Monitoring the Health of Children and Youth on SGAsGuidelines for Metabolic Monitoring; Recommendations for Monitoring Metabolic Changes; Height; Weight; Body Mass Index; Waist Circumference; Blood Pressure; Management of Metabolic Complications; Why Standardized Metabolic Monitoring Matters; Improving Patient Care; Educating Families; Overcoming Barriers to Completion of Monitoring; Conclusion; References; Chapter 5: Pediatric Clinical Trial Activity for Antipsychotics and the Sharing of Results: A Complex Ethical Landscape; Introduction; Patient Safety, Ethics, and Clinical Trial Regulation The Push for Pediatric Clinical TrialsThe Push for Clinical Trial Registration; Reporting of Results; Mapping the Landscape: Clinical Trials for Antipsychotics in Children and Youth; Methods; Results; Reflections On The Current State Of Pediatric Clinical Trials For Antipsychotics; The Landscape of Clinical Trial Activity; Developmental Gaps; The Strength of Evidence; Uniformity in Outcome Measures; Gaps in Results Reporting; Recruitment and Willingness to Participate in Research; Informed Consent; Limitations; Recommendations; References Chapter 6: Pathways to Overmedication and Polypharmacy: Case Examples from Adolescents with Fetal Alcohol Spectrum Disorders |
| Record Nr. | UNINA-9910819137803321 |
| Amsterdam, [Netherlands] : , : Academic Press, , 2015 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
